The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous radiofrequency ablation for primary or secondary lung cancers.
It replaces the previous guidance on Percutaneous radiofrequency ablation for primary or secondary lung cancers (NICE interventional procedures guidance 185, July 2006).
Percutaneous radiofrequency ablation of cancer in the lung involves inserting one or more electrodes (needle-like probes) through the chest into the lung. The electrodes are placed within the tumour and connected to a source of electrical current, producing heat with the aim of destroying (‘ablating’) the cancer cells.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.